There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
16 responses
55,155 views
0 reactions
|
by plant_hunt
11-06-2019, 05:43 AM
|
|||
|
0 responses
1,539 views
0 reactions
|
by francesca77
09-02-2013, 05:47 AM
|
|||
|
0 responses
1,634 views
0 reactions
|
by gberan
09-02-2013, 05:45 AM
|
|||
|
2 responses
2,752 views
0 reactions
|
by famarques
08-30-2013, 04:53 AM
|
|||
|
0 responses
2,449 views
0 reactions
|
by a.shamoun
08-30-2013, 03:05 AM
|
|||
|
5 responses
2,497 views
0 reactions
|
by vishnuamaram
08-29-2013, 09:30 PM
|
|||
|
0 responses
1,661 views
0 reactions
|
by rsharma1
08-29-2013, 11:36 AM
|
|||
|
0 responses
1,760 views
0 reactions
|
by steeljungle
08-27-2013, 10:34 AM
|
|||
|
0 responses
1,429 views
0 reactions
|
by OncoGenomics
08-26-2013, 06:17 AM
|
|||
|
0 responses
2,324 views
0 reactions
|
by bartg01
08-25-2013, 09:04 AM
|
|||
|
3 responses
3,108 views
0 reactions
|
by JackieBadger
08-23-2013, 09:53 AM
|
No topics found.
widgetinstance 229 (Webinars) skipped due to lack of content & hide_module_if_empty option.
-
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...Today, 05:17 AM -
Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.07-01-2026, 11:43 AM
-
I’m not a sequencing expert. I’m a purification scientist who uses NGS to evaluate workflows my group develops. With this perspective, we think about the sample first and the NGS workflow second. The sequencer is an exceptionally honest reporter, but it can only report on what you give it, so whether you get clean, interpretable data from an NGS workflow is largely determined before you begin.
Here are nine questions we think about, in roughly the order they matter, before...